M Windisch

Summary

Affiliation: Institute of Experimental Pharmacology
Country: Austria

Publications

  1. doi request reprint The role of alpha-synuclein in neurodegenerative diseases: a potential target for new treatment strategies?
    M Windisch
    Institute of Experimental Pharmacology, JSW Research, Graz, Austria
    Neurodegener Dis 5:218-21. 2008
  2. ncbi request reprint The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease
    Birgit Hutter-Paier
    JSW Research Forschungslabor GmbH, Institute of Experimental Pharmacology, Rankengasse 28, 8020 Graz, Austria
    Neuron 44:227-38. 2004
  3. ncbi request reprint N-PEP-12--a novel peptide compound that protects cortical neurons in culture against different age and disease associated lesions
    M Windisch
    JSW Research Forschungslabor GmbH, Graz, Austria
    J Neural Transm 112:1331-43. 2005
  4. ncbi request reprint Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?
    Manfred Windisch
    JSW Research, Forschungslabor Ltd, A 8020 Graz, Austria
    J Mol Neurosci 24:155-65. 2004
  5. ncbi request reprint The protective effect of ganstigmine against amyloid beta 25-35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition
    Manfred Windisch
    JSW Research Forschungslabor GmbH, Rankengasse 28, A 8020 Graz, Austria
    Neurosci Lett 341:181-4. 2003
  6. ncbi request reprint Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides
    Manfred Windisch
    JSW Research, Institute of Experimental Pharmacology, Graz, Austria
    J Mol Neurosci 19:63-9. 2002
  7. ncbi request reprint Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
    M Windisch
    JSW Research, Institute of Experimental Pharmacology, Rankengasse 28a, A 8020, Graz, Austria
    Curr Alzheimer Res 4:446-57. 2007
  8. ncbi request reprint Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
    Manfred Windisch
    JSW Research, Institute of Experimental Pharmacology, Rankengasse 28a, A 8020 Graz, Austria
    Curr Alzheimer Res 4:556-61. 2007
  9. ncbi request reprint Effects of NaCN and ionomycin on neuronal viability and on the abundance of microtubule-associated proteins MAP1, MAP2, and tau in isolated chick cortical neurons
    B Hutter-Paier
    Institute of Experimental Pharmacology, JSW Research, Graz, Austria
    Cell Tissue Res 302:39-47. 2000
  10. ncbi request reprint Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons
    M Hartbauer
    Institute of Zoology, Department of Neurobiology, Karl Franzens University, Graz, Austria
    J Neural Transm 108:459-73. 2001

Collaborators

Detail Information

Publications25

  1. doi request reprint The role of alpha-synuclein in neurodegenerative diseases: a potential target for new treatment strategies?
    M Windisch
    Institute of Experimental Pharmacology, JSW Research, Graz, Austria
    Neurodegener Dis 5:218-21. 2008
    ..The possibility that BS-derived peptidomimetics act as neuroprotectants and prevent protein misfolding suggests therapeutic usefulness...
  2. ncbi request reprint The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease
    Birgit Hutter-Paier
    JSW Research Forschungslabor GmbH, Institute of Experimental Pharmacology, Rankengasse 28, 8020 Graz, Austria
    Neuron 44:227-38. 2004
    ..Our results suggest that ACAT inhibition may be effective in the prevention and treatment of AD by inhibiting generation of the Abeta peptide...
  3. ncbi request reprint N-PEP-12--a novel peptide compound that protects cortical neurons in culture against different age and disease associated lesions
    M Windisch
    JSW Research Forschungslabor GmbH, Graz, Austria
    J Neural Transm 112:1331-43. 2005
    ..This indicates that chronic exposure to N-PEP-12 is able to prevent neuronal cell death associated to conditions occurring during normal aging and neurological disorders like ischemic stroke, hypoxia, brain trauma, or AD...
  4. ncbi request reprint Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?
    Manfred Windisch
    JSW Research, Forschungslabor Ltd, A 8020 Graz, Austria
    J Mol Neurosci 24:155-65. 2004
    ..Behavioral studies in APP transgenic mice were performed after 1 and 2 mo of treatment and showed clear effects of these peptides...
  5. ncbi request reprint The protective effect of ganstigmine against amyloid beta 25-35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition
    Manfred Windisch
    JSW Research Forschungslabor GmbH, Rankengasse 28, A 8020 Graz, Austria
    Neurosci Lett 341:181-4. 2003
    ..Because CHF3360 does not show any acetylcholine inhibitor activity in the applied dose range it is concluded that Ganstigmine provides significant neuroprotection independent from its cholinergic activity...
  6. ncbi request reprint Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides
    Manfred Windisch
    JSW Research, Institute of Experimental Pharmacology, Graz, Austria
    J Mol Neurosci 19:63-9. 2002
    ..Further smaller beta-synuclein-derived peptides have screened for antiaggregatory and neuroprotective potency in different tissue-culture systems. Preliminary data suggest some of them can be used as leads for further drug development...
  7. ncbi request reprint Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
    M Windisch
    JSW Research, Institute of Experimental Pharmacology, Rankengasse 28a, A 8020, Graz, Austria
    Curr Alzheimer Res 4:446-57. 2007
    ....
  8. ncbi request reprint Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
    Manfred Windisch
    JSW Research, Institute of Experimental Pharmacology, Rankengasse 28a, A 8020 Graz, Austria
    Curr Alzheimer Res 4:556-61. 2007
    ..The possibility that such betaS derived peptidomimetics might act as neuroprotectants and at the same time prevent protein missfolding suggests possible therapeutic usefulness in different neurodegenerative disorders...
  9. ncbi request reprint Effects of NaCN and ionomycin on neuronal viability and on the abundance of microtubule-associated proteins MAP1, MAP2, and tau in isolated chick cortical neurons
    B Hutter-Paier
    Institute of Experimental Pharmacology, JSW Research, Graz, Austria
    Cell Tissue Res 302:39-47. 2000
    ..Immunohistochemical experiments for MAP2 revealed that, compared with controls, NaCN and, to a much higher extent, IM treatment resulted in a loss of immunoreactivity in neurites due to progressing cell death...
  10. ncbi request reprint Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons
    M Hartbauer
    Institute of Zoology, Department of Neurobiology, Karl Franzens University, Graz, Austria
    J Neural Transm 108:459-73. 2001
    ..These findings ascertain an anti-apoptotic effect of the peptide fraction of Cerebrolysin and reveal a transient viability promoting effect of the amino acid fraction, which is most likely due to improved nutritional supply...
  11. ncbi request reprint Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window
    E Schauer
    JSW Research, Institute of Experimental Pharmacology, Graz, Austria
    J Neural Transm 113:855-68. 2006
    ..In conclusion the results indicate that Cere displays a relatively wide therapeutic time window which might be explained by a combination of acute neuroprotective properties and neurotrophic efficacy...
  12. ncbi request reprint A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication
    C Riley
    JSW Research, Institute of Experimental Pharmacology, Graz, Austria
    J Neural Transm 113:103-10. 2006
    ..A treatment after the lesion only also counteracted necrosis and apoptosis. The results render the drug relevant for treating acute as well as chronic neurodegenerative diseases...
  13. ncbi request reprint Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons
    M Hartbauer
    Institute of Zoology, Department of Neurobiology, Karl Franzens University, Graz, Austria
    J Neural Transm 108:581-92. 2001
    ....
  14. ncbi request reprint Early postnatal treatment with peptide preparations influences spatial navigation of young and adult rats
    A Gschanes
    Institute of Experimental Pharmacology, Research Initiative Ebewe, Graz, Austria
    Behav Brain Res 100:161-6. 1999
    ..Summarizing, early postnatal application of Cere or E021 improved the spatial learning and memory of young rats and led to long-lasting behavioural effects at least up to 3 months after treatment...
  15. ncbi request reprint Inhibitory effect of a brain derived peptide preparation on the Ca++-dependent protease, calpain
    R Wronski
    JSW Research, Graz, Austria
    J Neural Transm 107:145-57. 2000
    ..The clearly competitive inhibition of trypsin by the drug indicates distinct mechanisms and active components against different proteases...
  16. ncbi request reprint Two-color, fluorescence-based microplate assay for apoptosis detection
    Robert Wronski
    JSW Research, Graz, Austria
    Biotechniques 32:666-8. 2002
  17. ncbi request reprint Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: an immunohistochemical study on aged rats
    P Eder
    Institute of Experimental Pharmacology, JSW-Research, Graz, Austria
    Histochem J 33:605-12. 2001
    ..These results correlate with the behavioural outcome, revealing an improvement in learning and memory of these rats after treatment with Cerebrolysin and E021...
  18. doi request reprint Longitudinal magnetization transfer imaging in mild to severe Alzheimer disease
    S Ropele
    Department of Neurology, Medical University of Graz, Graz, Austria
    AJNR Am J Neuroradiol 33:570-5. 2012
    ..We therefore used a placebo-controlled study of memantine to follow the evolution of tissue damage in AD by means of MTR measurements and investigated how MTR changes were related to brain atrophy and cognition...
  19. ncbi request reprint Localization and expression of substance P in transgenic mice overexpressing human APP751 with the London (V717I) and Swedish (K670M/N671L) mutations
    Michael Willis
    Department of General Psychiatry, Medical University Innsbruck, Anichstrasse 35, A 6020 Innsbruck, Austria
    Brain Res 1143:199-207. 2007
    ..Future experiments including substance P antagonists are necessary to further explore the interaction between beta-amyloid deposits and substance P...
  20. ncbi request reprint Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease
    Chang Yi Wang
    United Biomedical Inc, 25 Davids Drive, Hauppauge, NY 11788, USA
    Vaccine 25:3041-52. 2007
    ..The vaccine was safe and well tolerated in adult Cynomolgus macaques during a repeat dose acute and chronic toxicity study...
  21. ncbi request reprint Chromogranin B and Secretogranin II in transgenic mice overexpressing human APP751 with the London (V717I) and Swedish (K670M/N671L) mutations and in Alzheimer patients
    Michael Willis
    Department of General Psychiatry, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
    J Alzheimers Dis 13:123-35. 2008
    ..Therefore specific changes of chromogranin peptides observed in Alzheimer patients can be related to amyloid-beta pathology only...
  22. doi request reprint Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology
    Stephan Schilling
    Probiodrug AG, Weinbergweg 22, 06120 Halle S, Germany
    Nat Med 14:1106-11. 2008
    ..The reduction of brain pE-Abeta by inhibition of glutaminyl cyclase offers a new therapeutic option for the treatment of Alzheimer's disease and provides implications for other amyloidoses, such as familial Danish dementia...
  23. doi request reprint The 8th International Conference on Alzheimer's and Parkinson's Diseases. Preface
    Israel Hanin
    Neurodegener Dis 5:113. 2008
  24. ncbi request reprint Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study
    X Anton Alvarez
    EuroEspes Biomedical Research Center, Santa Marta de Babia, 15166 Bergondo, A Coruna, Spain
    Int Clin Psychopharmacol 18:271-8. 2003
    ..These promising preliminary results suggest that Cerebrolysin might be a useful treatment to improve the recovery of patients with traumatic brain damage, and encourage the conduction of confirmatory clinical trials...
  25. ncbi request reprint Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein
    Edward Rockenstein
    Department of Neurosciences, University of California San Diego, School of Medicine, La Jolla, California 92093 0624, USA
    J Neurosci Res 80:247-59. 2005
    ..Furthermore, the PDGFbeta-halpha-synuclein-eGFP tg model might be a valuable tool in testing new treatments for LBD in a fast and reliable manner...